On May 19, 2022 Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, reported that John Butler, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference, which will take place as a hybrid event May 23–26, 2022 (Press release, Akebia, MAY 19, 2022, View Source/news-releases/news-release-details/akebia-therapeutics-present-hc-wainwright-global-investment" target="_blank" title="View Source/news-releases/news-release-details/akebia-therapeutics-present-hc-wainwright-global-investment" rel="nofollow">View Source [SID1234614874]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

An audio replay of the fireside chat will be available through the Investors section of Akebia’s website at View Source starting on May 24th and for approximately 90 days following the conference.